Is Bone Biologics going out of business?

Bone Biologics Corp (BBLG) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Bone Biologics Corp (BBLG) fundamentals, assembled from SEC filings.

Five questions, kept separate

Survival - Fragile

Runway cannot be estimated from the available cash and cash-flow fields. Adjusted shares outstanding increased 230.0% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Evidence incomplete

The current price is available, but the filing does not contain enough applicable valuation evidence to interpret it.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 3 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 229.98% (YoY)
• Filing event risk: Going-Concern Warning (-8 pts)
• Return on Assets: -70.07%
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-28.

Price as of 2026-09-09.